MGX Metagenomi Inc

Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

WFH 2024 World CongressMadrid, SpainApril 21-24, 2024

Oral Presentation Title: Metagenomi:Potentially Curative Gene Editing Approach for Hemophilia ASession: Late breaking session: New techLocation: N103+N104Date / time: Tuesday, April 23, 2024, 16:00 – 17:00 CEST

ASGCT 2024 Annual MeetingBaltimore, MDMay 7-9, 2024

Poster Title: Novel CRISPR Effectors and Reverse Transcriptases Discovered from Metagenomics Enable Extensive Remodeling of the Human GenomeAbstract Number: 1209Location: Exhibit HallDate / time: Thursday, May 9, 2024, 12:00 p.m. ET

Poster Title: Novel and Efficient Base Editors Engineered to Comprehensively Target the Human GenomeAbstract Number: 684Location: Exhibit HallDate / time: Wednesday, May 8, 2024, 12:00 p.m. ET

All presentations will be made available on the "News & Events," page in the Investors section of the Company's website at https://ir.metagenomi.co/news-events/events.

About Metageno­mi

Metageno­mi is a pre­ci­sion genet­ic med­i­cines com­pa­ny com­mit­ted to devel­op­ing cura­tive ther­a­peu­tics for patients using its pro­pri­etary, com­pre­hen­sive metage­­nomics-derived tool­box. Metageno­mi is har­ness­ing the pow­er of metage­nomics, the study of genet­ic mate­r­i­al recov­ered from the nat­ur­al envi­ron­ment, to unlock four bil­lion years of micro­bial evo­lu­tion to dis­cov­er and devel­op a suite of nov­el edit­ing tools capa­ble of cor­rect­ing any type of genet­ic muta­tion found any­where in the genome. Its com­pre­hen­sive genome edit­ing tool­box includes pro­gram­ma­ble nucle­as­es, base edi­tors, and RNA and DNA-medi­at­ed inte­gra­tion sys­tems (includ­ing prime edit­ing sys­tems and clus­tered reg­u­lar­ly inter­spaced short palin­dromic repeat-asso­­ci­at­ed trans­posas­es). Metageno­mi believes its diverse and mod­u­lar tool­box posi­tions the com­pa­ny to access the entire genome and select the opti­mal tool to unlock the full poten­tial of genome edit­ing for patients. For more infor­ma­tion, please vis­it https://​metageno​mi​.co.

Cautionary Note Regarding Forward‐​Looking Statements

This press release con­tains ​“for­ward-look­ing state­ments” with­in the mean­ing of Sec­tion 27A of the Secu­ri­ties Act of 1933 and Sec­tion 21E of the Secu­ri­ties Exchange Act of 1934, each as amend­ed. Such state­ments, which are often indi­cat­ed by terms such as ​“antic­i­pate,” ​“believe,” ​“could,” ​“esti­mate,” ​“expect,” ​“goal,” ​“intend,” ​“look for­ward to,” ​“may,” ​“plan,” ​“poten­tial,” ​“pre­dict,” ​“project,” ​“should,” ​“will,” ​“would” and sim­i­lar expres­sions, include, but are not lim­it­ed to, any state­ments relat­ing to our growth strat­e­gy and prod­uct devel­op­ment pro­grams, includ­ing the tim­ing of and our abil­i­ty to con­duct IND-enabling stud­ies, make reg­u­la­to­ry fil­ings such as INDs and oth­er appli­ca­tions and to obtain reg­u­la­to­ry approvals for our prod­uct can­di­dates, state­ments con­cern­ing the poten­tial of ther­a­pies and prod­uct can­di­dates, and any oth­er state­ments that are not his­tor­i­cal facts. For­ward-look­ing state­ments are based on management’s cur­rent expec­ta­tions and are sub­ject to risks and uncer­tain­ties that could neg­a­tive­ly affect our busi­ness, oper­at­ing results, finan­cial con­di­tion and stock val­ue. Fac­tors that could cause actu­al results to dif­fer mate­ri­al­ly from those cur­rent­ly antic­i­pat­ed include: risks relat­ing to our growth strat­e­gy; our abil­i­ty to obtain, per­form under, and main­tain financ­ing and strate­gic agree­ments and rela­tion­ships; risks relat­ing to the results of research and devel­op­ment activ­i­ties; risks relat­ing to the tim­ing of start­ing and com­plet­ing clin­i­cal tri­als; uncer­tain­ties relat­ing to pre­clin­i­cal and clin­i­cal test­ing; our depen­dence on third-par­ty sup­pli­ers; our abil­i­ty to attract, inte­grate and retain key per­son­nel; the ear­ly stage of prod­ucts under devel­op­ment; our need for sub­stan­tial addi­tion­al funds; gov­ern­ment reg­u­la­tion; patent and intel­lec­tu­al prop­er­ty mat­ters; com­pe­ti­tion; as well as oth­er risks described in ​“Risk Fac­tors,” in our most recent Form 10-K, on fil­e with the SEC. We express­ly dis­claim any oblig­a­tion or under­tak­ing to release pub­licly any updates or revi­sions to any for­ward-look­ing state­ments con­tained here­in to reflect any change in our expec­ta­tions or any changes in events, con­di­tions or cir­cum­stances on which any such state­ment is based, except as required by law, and we claim the pro­tec­tion of the safe har­bor for for­ward-look­ing state­ments con­tained in the Pri­vate Secu­ri­ties Lit­i­ga­tion Reform Act of 1995.

Investor Con­tact:Simon Harnest CIO, SVP Investor Relationssimon@​metagenomi.​co

Media Con­tact:Ash­lye Hodge, Com­mu­ni­ca­tions Man­ag­erashlye@​metagenomi.​co